Search Results

HER-2 targeted treatment of osteosarcoma: the challenges of developing targeted therapy and prognostic factors for rare malignancies

Authors: Geller, David S; Gorlick, Richard

Source: Expert Opinion on Pharmacotherapy, Volume 11, Number 1, January 2010 , pp. 51-61(11)

Publisher: Informa Healthcare

Microglandular adenosis or microglandular adenoma? A molecular genetic analysis of a case associated with atypia and invasive carcinoma

Authors: Geyer, Felipe C; Kushner, Yael B; Lambros, Maryou B; Natrajan, Rachael; Mackay, Alan; Tamber, Narinder; Fenwick, Kerry; Purnell, Dave; Ashworth, Alan; Walker, Rosemary A; Reis-Filho, Jorge S

Source: Histopathology, Volume 55, Number 6, December 2009 , pp. 732-743(12)

Publisher: Blackwell Publishing

Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with ⁶⁴Cu-DOTA-trastuzumab

Authors: Niu, Gang; Li, Zibo; Cao, Qizhen; Chen, Xiaoyuan

Source: European Journal of Nuclear Medicine and Molecular Imaging, Volume 36, Number 9, September 2009 , pp. 1510-1519(10)

Publisher: Springer

Prognostic significance of molecular classification of breast invasive ductal carcinoma

Authors: Muñoz, Mar; Fernández-Aceñero, M.; Martín, Silvia; Schneider, José

Source: Archives of Gynecology and Obstetrics, Volume 280, Number 1, July 2009 , pp. 43-48(6)

Publisher: Springer

Lapatinib as a Chemotherapeutic Drug

Author: Obajimi, Oluwakemi

Source: Recent Patents on Anti-Cancer Drug Discovery, Volume 4, Number 3, November 2009 , pp. 216-226(11)

Publisher: Bentham Science Publishers

Influence of obesity on breast cancer receptor status and prognosis

Authors: Rose, David P; Vona-Davis, Linda

Source: Expert Review of Anticancer Therapy, Volume 9, Number 8, August 2009 , pp. 1091-1101(11)

Publisher: Expert Reviews

The effects of obesity and HER-2 polymorphisms as risk factors for endometrial cancer in Korean women

Authors: Tong, S-Y; Ha, S-Y; Ki, K-D; Lee, J-M; Lee, S-K; Lee, K-B; Kim, M-K; Cho, C-H; Kwon, S-Y

Source: BJOG: An International Journal of Obstetrics & Gynaecology, Volume 116, Number 8, July 2009 , pp. 1046-1052(7)

Publisher: Blackwell Publishing

HER-2 Signaling and Inhibition in Breast Cancer

Authors: Browne, B. C.; O'Brien, N.; Duffy, M. J.; Crown, J.; O'Donovan, N.

Source: Current Cancer Drug Targets, Volume 9, Number 3, May 2009 , pp. 419-438(20)

Publisher: Bentham Science Publishers

Coexpression of the melatonin receptor 1 and nestin in human breast cancer specimens

Authors: Rögelsperger, O.; Ekmekcioglu, C.; Jäger, W.; Klimpfinger, M.; Königsberg, R.; Krenbek, D.; Sellner, F.; Thalhammer, T.

Source: Journal of Pineal Research, Volume 46, Number 4, May 2009 , pp. 422-432(11)

Publisher: Blackwell Publishing

Oncogene-Driven Hemostatic Changes in Cancer

Authors: Rak, Janusz; Yu, Joanne; Milsom, Chloe

Source: Cancer Investigation, Volume 27, Supplement 1, 2009 , pp. 28-35(8)

Publisher: Informa Healthcare

Rapid screening of tissue microarrays for Her-2 fluorescence in situ hybridization testing is an accurate, efficient and economic method of providing an entirely in situ hybridization-based Her-2 testing service

Authors: Faratian, Dana; Graham, Ashley; Rae, Frances; Thomas, Jeremy

Source: Histopathology, Volume 54, Number 4, March 2009 , pp. 428-432(5)

Publisher: Blackwell Publishing

Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer

Authors: Andreetta, C.; Puppin, C.; Minisini, A.; Valent, F.; Pegolo, E.; Damante, G.; Di Loreto, C.; Pizzolitto, S.; Pandolfi, M.; Fasola, G.; Piga, A.; Puglisi, F.

Source: Annals of Oncology, Volume 20, Number 2, 14 February 2009 , pp. 265-271(7)

Publisher: Oxford University Press

YB-1 prevents apoptosis via the mTOR/STAT3 pathway in HER-2-overexpressing breast cancer cells

Authors: Fujii, Teruhiko; Seki, Naoko; Namoto-Matsubayashi, Roka; Takahashi, Hiroki; Inoue, Yuka; Toh, Uhi; Kage, Masayoshi; Shirouzu, Kazuo

Source: Future Oncology, Volume 5, Number 2, March 2009 , pp. 153-156(4)

Publisher: Future Medicine

Aromatase Inhibitors and Breast Cancer

Authors: Macedo, Luciana Furtado; Sabnis, Gauri; Brodie, Angela

Source: Annals of the New York Academy of Sciences, Volume 1155, Number 1, February 2009 , pp. 162-173(12)

Publisher: Blackwell Publishing

Beyond Trastuzumab: Overcoming Resistance to Targeted HER-2 Therapy in Breast Cancer

Authors: Bedard, Philippe L.; de Azambuja, Evandro; Cardoso, Fatima

Source: Current Cancer Drug Targets, Volume 9, Number 2, March 2009 , pp. 148-162(15)

Publisher: Bentham Science Publishers

A two-component drug delivery system using Her-2-targeting thermosensitive liposomes

Authors: Kullberg, Max; Mann, Kristine; Owens, Jesse Lee

Source: Journal of Drug Targeting, Volume 17, Number 2, February 2009 , pp. 98-107(10)

Publisher: Informa Healthcare

Associations between the uptake of ¹¹¹In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts

Authors: McLarty, Kristin; Cornelissen, Bart; Scollard, Deborah; Done, Susan; Chun, Kathy; Reilly, Raymond

Source: European Journal of Nuclear Medicine and Molecular Imaging, Volume 36, Number 1, January 2009 , pp. 81-93(13)

Publisher: Springer

High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer

Authors: Mir, O.; Ropert, S.; Alexandre, J.; Lemare, F.; Goldwasser, F.

Source: Annals of Oncology, Volume 19, Number 11, 13 November 2008 , pp. 1978-1980(3)

Publisher: Oxford University Press

YB-1 als potenzielles Ziel für die Tumortherapie

Authors: Lage, H.; Surowiak, P.; Holm, P.S.

Source: Der Pathologe, Volume 29, Supplement 1, November 2008 , pp. 187-190(4)

Publisher: Springer

The clinical significance of hMAM mRNA expression in peripheral blood of patients with breast cancer

Authors: Xie, Xiaodong; Zhang, Fang; Zheng, Zhendong; Qu, Shuxian

Source: The Chinese-German Journal of Clinical Oncology, Volume 7, Number 12, December 2008 , pp. 709-712(4)

Publisher: Springer